Trials Sponsors Conditions Drugs Pricing

Conditions

Arrhythmia

Keywords

Palpitations

Outcome Measures

Primary Outcomes (1)

Improvement in symptoms
Assessment of improvement in palpitations using a questionnaire. The improvement will be graded either non, mild, moderate, or great. The result will either negative (no or mild improvement), or positive (moderate or great improvement)
10 days after starting treatment

Study Arms (2)

Active treatment

EXPERIMENTAL

The treatment will consist of lanzoprazole 30 mg once daily at night time

Drug: Lansoprazole Pill

Placebo

PLACEBO COMPARATOR

A Placebo pill to be given with similar looking to experimental drug but contains inactive ingredient

Drug: Placebo

Interventions

Lansoprazole PillDrug

once daily at night time

Also known as: Lanzotec

Active treatment

PlaceboDrug

Placebo

Eligibility Criteria

Age16 Years - 99 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

Persons with palpitations and no clear cause who are above the age of 16 years and who consent to the study will be included
Clear causes that should be excluded are true arrhythmia such SVT or VT or frequent premature atrial or ventricular contractions or any organic cause such as thyroid disorder, anemia (hg less than 11 g/dl) and obvious anxiety disorder

Sponsors & Collaborators

University of Jordan
Othercollaborator
Jordan Collaborating Cardiology Group
Otherlead

Study Sites (1)

The University of Jordan

Amman, 11942, Jordan

MeSH Terms

Conditions

Arrhythmias, Cardiac

Interventions

Lansoprazole

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

2-PyridinylmethylsulfinylbenzimidazolesSulfoxidesSulfur CompoundsOrganic ChemicalsPyridinesHeterocyclic Compounds, 1-Ring

Study Officials

Omar Ubaidat, MD
Jordan University Hospital
STUDY CHAIR

Enrollment

150 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, CARE PROVIDER
Masking Details: Similarly looking tablets and placebo with care providers not knowing which is which. Packets are marked "heads and tails" for randomization
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 21, 2017

First Posted

September 6, 2017

Study Start

May 20, 2017

Actual (reported)

The Effect of Proton Pump Inhibition on Palpitations

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Active treatment

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Active treatment

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations